16 institutional investors are raising stakes in Anthera Pharmaceuticals, Inc. (ANTH)

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) enjoyed a 36.67% run-up in share price since hitting record low of $1.22. The stock managed 6.49% rise and now stands at $1.64 as of Oct. 18, 2017. At recent session, the prices were hovering between $1.64 and $1.64. This company shares are 311.59% off its target price of $6.75 and the current market capitalization stands at $18.6M. The recent change has given its price a 12.99% lead over SMA 50 and -93.03% deficit over its 52-week high. The stock witnessed 28.13% gains, 5.13% gains and -49.54% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ANTH’s volatility during a week at 7.72% and during a month it has been found around 9.47%.

Anthera Pharmaceuticals, Inc. (ANTH) Top Holders

Institutional investors currently hold around $5 million or 29.2% in ANTH stock. Look at its top three institutional owners. Bvf Inc/Il owns $1.55 million in Anthera Pharmaceuticals, Inc., which represents roughly 8.33% of the company’s market cap and approximately 31% of the institutional ownership. Similar statistics are true for the second largest owner, Sabby Management, Llc, which owns 592,672 shares of the stock are valued at $913 thousand. The third largest holder is Vanguard Group Inc, which currently holds $525 thousand worth of this stock and that ownership represents nearly 2.82% of its market capitalization.

Anthera Pharmaceuticals, Inc. 13F Filings

At the end of June reporting period, 16 institutional holders increased their position in Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) by some 749,067 shares, 48 decreased positions by 1,372,906 and 4 held positions by 823,954. That puts total institutional holdings at 2,945,927 shares, according to SEC filings. The stock grabbed 6 new institutional investments totaling 160,887 shares while 30 institutional investors sold out their entire positions totaling 794,960 shares.

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Insider Trades

Multiple company employees have indulged in significant insider trading. Anthera Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that President & CEO Thompson John Craig has acquired 8,550 shares of Anthera Pharmaceuticals, Inc. (ANTH) in trading session dated Sep. 20, 2017. These shares are worth $11,286 and were traded at $1.32 each. The SEC filing shows that Thompson John Craig performed a purchase of 10,400 shares. The President & CEO added these shares by way of transaction on Sep. 07, 2017. The company’s shares were assimilated at $1.43 per share worth to an investment of some $14,872 on account of Thompson John Craig.

Director, Truex Paul F, purchased 5,000 common shares of Anthera Pharmaceuticals, Inc. (ANTH) in the open market. In a transaction dated Sep. 07, 2017, the shares were bought at an average price of $1.34, giving away a sum of $6,700. After this purchase, 16,793 common shares of ANTH are directly owned by the insider, with total stake valued at $27,541.

In the transaction dated Nov. 13, 2015, the great number of shares disposed came courtesy the Chief Medical Officer; Hislop Colin disposed a total of 1,563 shares at an average price of $42.48, amounting to approximately $66,396. The insider now directly owns 2,631 shares worth $4,315.

Anthera Pharmaceuticals, Inc. (ANTH) Analyst Guide

Several analysts have released their opinion on Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), with 1 analysts believing it is a strong buy. Whereas 2 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2.33 average brokerage recommendation.

SHARE
Previous articleWhich insiders are trading MobileIron, Inc. (MOBL)?
Next articleVanguard Group Inc is the second biggest holder of BioMarin Pharmaceutical Inc. (BMRN)